Reported Earlier, Enliven To Present New ELVN-001 Blood Cancer Trial Data At September Medical Meeting
Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company
Enliven is showing new test results for a blood cancer medicine at a big doctor meeting in September. When a company shares new medicine test results, it's a chance to see if their treatment is working—keep an eye on whether doctors think the results are encouraging.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.